InvestorsHub Logo
Followers 484
Posts 61016
Boards Moderated 18
Alias Born 09/20/2001

Re: jamtomorrow2 post# 4864

Tuesday, 11/08/2016 6:53:50 AM

Tuesday, November 08, 2016 6:53:50 AM

Post# of 8758
As long as they continue to fail....

This statement does not sound like Pfizer is trying to do an end run around HALO though, the problem seems to be with the compound itself and/or the competitive landscape.

Pfizer announcing discontinuation of the global clinical development program for bococizumab, its investigational PCSK9 inhibitor. The development of a subcutaneous version on the Halozyme ENHANZE platform has also been discontinued. Pfizer also made a portfolio decision to discontinue development of rivipansel with the ENHANZE platform even though the technology performed as intended. Pfizer continues to develop an additional program with the ENHANZE platform for an undisclosed target.



http://ih.advfn.com/p.php?pid=nmona&article=72851618





In Peace, In War

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News